文章核心观点 - ALX Oncology Holdings Inc.（一家临床阶段的生物技术公司）宣布任命Alan Sandler博士为首席医疗官[1] 相关目录总结 任命理由 - 公司首席执行官表示Sandler博士在肿瘤学和药物开发方面经验丰富领导能力强且对公司了解深入有助于实现公司近远期目标是推动公司主要化合物evorpacept进入后期临床试验的理想领导者[2] Sandler博士履历 - 曾在Mirati Therapeutics担任执行副总裁兼首席医疗官在被Bristol Myers Squibb收购之前还在Zai Lab担任肿瘤开发全球负责人在Genentech担任多个重要职位包括高级副总裁等在多所大学担任学术职位[2] Sandler博士对新职位的展望 - 曾作为董事会成员见证公司领导团队和evorpacept的临床活动期待在新职位上继续开发该疗法以改善多种肿瘤类型和治疗环境下的患者预后[3] Sandler博士教育背景及著作 - 从Rush Medical College获得医学博士学位在Yale - New Haven Medical Center完成内科培训和肿瘤学研究金共合著300多篇出版物[3] 公司概况 - ALX Oncology是临床阶段生物技术公司致力于开发提升免疫系统的疗法来治疗癌症并延长患者生命其主要候选疗法evorpacept有潜力成为免疫肿瘤学未来的基石疗法正在多个癌症适应症的临床试验中接受评估[4]

An economics graduate with a passion for financial history; I apply my knowledge to markets in an effort to hopelessly predict trends and spot value. All opinions are my own and should not be taken seriously.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ...

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients’ lives, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update. “We made substantial clinical progress during the third quarter, most notably announcing topline data from our AS ...

Alexander's (ALX) came out with quarterly funds from operations (FFO) of $2.84 per share, beating the Zacks Consensus Estimate of $2.57 per share. This compares to FFO of $3.63 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an FFO surprise of 10.51%. A quarter ago, it was expected that this real estate investment trust would post FFO of $2.57 per share when it actually produced FFO of $3.31, delivering a surprise of 28.79%.Over the last four quarter ...

PARAMUS, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- ALEXANDER’S, INC. (New York Stock Exchange: ALX) filed its Form 10-Q for the quarter ended September 30, 2024 today and reported: Third Quarter 2024 Financial Results Net income for the quarter ended September 30, 2024 was $6.7 million, or $1.30 per diluted share, compared to $10.8 million, or $2.10 per diluted share for the quarter ended September 30, 2023. Funds from operations (“FFO”) (non-GAAP) for the quarter ended September 30, 2024 was $14.6 million, o ...

财务业绩 - 公司第三季度净收入为6,678,000美元，每股摊薄收益为1.30美元[67] - 公司第三季度基金营运收益(FFO,非GAAP)为14,582,000美元，每股摊薄收益为2.84美元[67] - 公司第三季度租金收入为55,675,000美元，较上年同期增加262,000美元[78] - 公司第三季度运营费用为26,446,000美元，较上年同期增加853,000美元[79] - 公司第三三季度利息和债务费用为19,261,000美元，较上年同期增加3,086,000美元[83] - 公司第三季度利息和其他收入为6,105,000美元，较上年同期减少517,000美元[82] - 公司2024年9个月的FFO为57,123,000美元，同比增长3%[102] - 公司2024年9个月的FFO每股收益为11.13美元，同比增长3%[102] 资产负债管理 - 公司于2024年6月11日将731 Lexington Avenue物业的5亿美元贷款展期4个月并偿还1,000万美元本金[70] - 公司于2024年9月30日为731 Lexington Avenue物业的办公部分签订了4亿美元的新贷款,利率为5.04%,到期日为2028年10月[71] - 截至2024年9月30日的9个月现金及现金等价物和受限现金为397,176,000美元，较2023年12月31日的552,977,000美元减少155,801,000美元[93] - 2024年9个月经营活动产生的现金净流入为23,296,000美元，其中包括净收入31,167,000美元和非现金项目调整45,349,000美元[93] - 2024年9个月投资活动使用的现金净额为3,273,000美元，主要用于在建工程和房地产添置9,836,000美元[93] - 2024年9个月筹资活动使用的现金净额为175,824,000美元，主要包括偿还债务500,000,000美元和支付股利69,277,000美元[93] 资产处置 - 公司于2023年5月19日以7,106万美元的价格出售了Rego Park III地块,获得净收益6,782.1万美元[72] 风险管理 - 公司持有1.7亿美元的一般责任险和财产险额度，其中30,000,000美元包括传染病保险[96] - 公司的全资子公司Fifty Ninth Street Insurance Company, LLC为恐怖主义行为(包括核生化武器)提供高达17亿美元的保险[97] 主要租户风险 - 公司主要租户彭博社(Bloomberg)占公司租金收入的55%,如果失去该租户将对公司业绩产生不利影响[75]

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients’ lives, today announced that results from a Phase 1b/2 combination trial evaluating ALX Oncology’s evorpacept in combination with Jazz Pharmaceuticals’ zanidatamab in HER2-positive and HER2-low metastatic breast cancer have been accept ...

PARAMUS, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Alexander’s, Inc. (NYSE: ALX) today announced that it will file its quarterly report on Form 10-Q for the quarter ended September 30, 2024 with the U.S. Securities and Exchange Commission and issue its third quarter earnings release on Monday, November 4, 2024, before the New York Stock Exchange opens. Vornado Realty Trust (NYSE: VNO), the manager which conducts Alexander’s operations, announced it will host its quarterly earnings conference call and an audio ...

Greenridge Exploration Enters into Binding Arrangement Agreement to Acquire ALX Resources Corp.NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESOctober 11, 2024 2:12 PM EDT | Source: ALX Resources Corp.Vancouver, British Columbia--(Newsfile Corp. - October 11, 2024) - Greenridge Exploration Inc. (CSE: GXP) (FSE: HW3)  ("Greenridge" or the "Company") and ALX Resources Corp. ("ALX" and collectively with Greenridge, the "Parties") (TSXV: AL) (FSE: 6 ...

PARAMUS, N.J., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Alexander’s, Inc. (NYSE: ALX) today announced that it has completed a $400 million refinancing of the office condominium portion of 731 Lexington Avenue, the Class A Bloomberg LP headquarters building. The interest-only loan carries a fixed rate of 5.045% and matures in October 2028. The loan is prepayable, at Alexander’s option, with no penalty, beginning in October 2026. The loan replaces the prior $490 million loan on the office condominium, that bore int ...